Differential involvement of 5-HT1A and 5-HT1B/1D receptors in human interferon-alpha-induced immobility in the mouse forced swimming test

Arzneimittel-Forschung/Drug Research

Volumn 60, Issue 3, 2010, Pages 109-115

  Zhang, Hongmei ^a   Wang, Wei ^a   Jiang, Zhenzhou ^a   Shang, Jing ^a   Zhang, Luyong ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

CAS 9008 11 1; Depression; Forced swimming test; Interferon alpha

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 4 (4 METHYL 1 PIPERAZINYL) 7 TRIFLUOROMETHYLPYRROLO[1,2 A]QUINOXALINE; ALPHA INTERFERON; ANTIDEPRESSANT AGENT; BUSPIRONE; CAS 36505 84 7; FLUOXETINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; SEROTONIN 1A RECEPTOR; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; FORCED SWIMMING TEST; IMMOBILIZATION; MALE; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION;

EID: 77950618782     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296258     Document Type: Article

References (52)

1. Siegal FP, Kadowaki N, Shodell M, Fitzgerald-Bocarsly PA, Shah K, Ho S, et al. The nature of the principal type 1 interferon- producing cells in human blood. Science. 1999; 284(5421):1835-7.
2. Cella M, Jarrossay D, Facchetti F, Alebardi O, Nakajima H, Lanzavecchia A, et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med. 1999;5(8):919-23.
3. Asselin-Paturel C, Boonstra A, Dalod M, Durand I, Yessaad N, Dezutter-Dambuyant C, et al. Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat Immunol. 2001;2(12):1144-50.
4. Bjorck P. Isolation and characterization of plasmacytoid dendritic cells from Flt3 ligand and granulocyte-macrophage colony-stimulating factor-treated mice. Blood. 2001;98(13):3520-6.
5. Delhaye S, Paul S, Blakqori G, Minet M, Weber F, Staeheli P, et al. Neurons produce type I interferon during viral encephalitis. Proc Natl Acad Sci USA. 2006;103(20):7835-40.
6. Tedeschi B, Barrett JN, Keane RW. Astrocytes produce interferon that enhances the expression of H-2 antigens on a subpopulation of brain cells. J Cell Biol. 1986;102(6): 2244-53.
7. Ward LA, Massa PT. Neuron-specific regulation of major histocompatibility complex class I, interferon-beta, and anti-viral state genes. J Neuroimmunol. 1995;58(2):145-55.
8. Baron S, Tyring SK, Fleischmann WR, Jr., Coppenhaver DH, Niesel DW, Klimpel GR, et al. The interferons. Mechanisms of action and clinical applications. JAMA. 1991; 266(10):1375-83.
9. Steinmann GG, Rosenkaimer F, Leitz G. Clinical experiences with interferon-alpha and interferon-gamma. Int Rev Exp Pathol. 1993;34 Pt B:193-207.
10. Schiepers OJ, Wichers MC, Maes M. Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(2):201-17.
11. Bonaccorso S, Marino V, Biondi M, Grimaldi F, Ippoliti F, Maes M. Depression induced by treatment with interferon- alpha in patients affected by hepatitis C virus. J Affect Disord. 2002;72(3):237-41.
12. Malaguarnera M, Laurino A, Di Fazio I, Pistone G, Castorina M, Guccione N, et al. Neuropsychiatric effects and type of IFN-alpha in chronic hepatitis C. J Interferon Cytokine Res. 2001;21(5):273-8.
13. Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M. Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy. J Clin Psychiatry. 2003; 64(6):708-14.
14. Otsubo T, Miyaoka H, Kamijima K, Onuki M, Ishii M, Mitamura K. [Depression during interferon therapy in chronic hepatitis C patients - a prospective study]. Seishin Shinkeigaku Zasshi. 1997;99(3):101-27.
15. Constant A, Castera L, Dantzer R, Couzigou P, de Ledinghen V, Demotes-Mainard J, et al. Mood alterations during interferon-alfa therapy in patients with chronic hepatitis C: evidence for an overlap between manic/hypomanic and depressive symptoms. J Clin Psychiatry. 2005;66(8): 1050-7.
16. Loftis JM, Socherman RE, Howell CD, Whitehead AJ, Hill JA, Dominitz JA, et al. Association of interferon-alpha-induced depression and improved treatment response in patients with hepatitis C. Neurosci Lett. 2004;365(2):87-91.
17. Ademmer K, Beutel M, Bretzel R, Jaeger C, Reimer C. Suicidal ideation with IFN-alpha and ribavirin in a patient with hepatitis C. Psychosomatics. 2001;42(4):365-7.
18. Fukunishi K, Tanaka H, Maruyama J, Takahashi H, Kitagishi H, Ueshima T, et al. Burns in a suicide attempt related to psychiatric side effects of interferon. Burns. 1998; 24(6):581-3.
19. Valentine AD. Managing the neuropsychiatric adverse effects of interferon treatment. BioDrugs. 1999;11(4):229-37.
20. Hauser P. Neuropsychiatric side effects of HCV therapy and their treatment: focus on IFN alpha-induced depression. Gastroenterol Clin North Am. 2004;33(1 Suppl):S35-50.
21. Blier P, Bergeron R. Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol. 1995;15(3):217-22.
22. Redrobe JP, MacSweeney CP, Bourin M. The role of 5-HT1A and 5-HT1B receptors in antidepressant drug actions in the mouse forced swimming test. Eur J Pharmacol. 1996;318(2-3):213-20.
23. O'Neill MF, Conway MW. Role of 5-HT(1A) and 5-HT(1B) receptors in the mediation of behavior in the forced swim test in mice. Neuropsychopharmacology. 2001;24(4):391-8.
24. Berrocoso E, Rojas-Corrales MO, Mico JA. Differential role of 5-HT1A and 5-HT1B receptors on the antinociceptive and antidepressant effect of tramadol in mice. Psychopharmacology (Berl). 2006;188(1):111-8.
25. Tatarczynska E, Klodzinska A, Stachowicz K, Chojnacka-Wojcik E. Effect of combined administration of 5-HT1A or 5-HT1B/1D receptor antagonists and antidepressants in the forced swimming test. Eur J Pharmacol. 2004;487(1-3): 133-42.
26. Wills RJ. Clinical pharmacokinetics of interferons. Clin Pharmacokinet. 1990;19(5):390-9.
27. Wiranowska M, Wilson TC, Thompson K, Prockop LD. Cerebral interferon entry in mice after osmotic alteration of blood-brain barrier. J Interferon Res. 1989;9(3):353-62.
28. Smith RA, Norris F, Palmer D, Bernhardt L, Wills RJ. Distribution of alpha interferon in serumand cerebrospinal fluid after systemic administration. Clin Pharmacol Ther. 1985;37(1):85-8.
29. Mattson K, Niiranen A, Iivanainen M, Farkkila M, Bergstrom L, Holsti LR, et al. Neurotoxicity of interferon. Cancer Treat Rep. 1983;67(10):958-61.
30. Makino M, Kitano Y, KomiyamaC, Hirohashi M, Takasuna K. Involvement of central opioid systems in human interferon-alpha induced immobility in the mouse forced swimming test. Br J Pharmacol. 2000;130(6):1269-74. (Pubitemid 30488589)
31. Fahey B, Hickey B, Kelleher D, O'Dwyer AM, O'Mara SM. The widely-used anti-viral drug interferon-alpha induces depressive- and anxiogenic-like effects in healthy rats. Behav Brain Res. 2007;182(1):80-7.
32. Makino M, Kitano Y, Komiyama C, Takasuna K. Human interferon-alpha increases immobility in the forced swimming test in rats. Psychopharmacology (Berl). 2000;148(1): 106-10.
33. Makino M, Kitano Y, Hirohashi M, Takasuna K. Enhancement of immobility in mouse forced swimming test by treatment with human interferon. Eur J Pharmacol. 1998; 356(1):1-7.
34. Sari Y. Serotonin 1B receptors: from protein to physiological function and behavior. Neurosci Biobehav Rev. 2004; 28(6):565-82.
35. Albert PR, Lemonde S. 5-HT1A receptors, gene repression, and depression: guilt by association. Neuroscientist. 2004; 10(6):575-93.
36. Borsini F, Meli A. Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology (Berl). 1988;94(2):147-60.
37. Coppen A. The biochemistry of affective disorders. Br J Psychiatry. 1967;113(504):1237-64.
38. Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol. 2002;22(1): 86-90.
39. Kamata M, Higuchi H, Yoshimoto M, Yoshida K, Shimizu T. Effect of single intracerebroventricular injection of alphainterferon on monoamine concentrations in the rat brain. Eur Neuropsychopharmacol. 2000;10(2):129-32.
40. Lucki I, Singh A, Kreiss DS. Antidepressant-like behavioral effects of serotonin receptor agonists. Neurosci Biobehav Rev. 1994;18(1):85-95.
41. Skingle M, Sleight AJ, Feniuk W. Effects of the 5-HT1D receptor antagonist GR127935 on extracellular levels of 5-HT in the guinea-pig frontal cortex as measured by microdialysis. Neuropharmacology. 1995;34(4):377-82.
42. Sharp T, Umbers V, Gartside SE. Effect of a selective 5-HT reuptake inhibitor in combination with 5-HT1A and 5-HT1B receptor antagonists on extracellular 5-HT in rat frontal cortex in vivo. Br J Pharmacol. 1997;121(5):941-6.
43. Hjorth S, Westlin D, Bengtsson HJ. WAY100635-induced augmentation of the 5-HT-elevating action of citalopram: relative importance of the dose of the 5-HT1A (auto)receptor blocker versus that of the 5-HT reuptake inhibitor. Neuropharmacology. 1997;36(4-5):461-5.
44. Invernizzi R, Bramante M, Samanin R. Role of 5-HT1A receptors in the effects of acute chronic fluoxetine on extracellular serotonin in the frontal cortex. Pharmacol Biochem Behav. 1996;54(1):143-7.
45. Gartside SE, Umbers V, Hajos M, Sharp T. Interaction between a selective 5-HT1A receptor antagonist and an SSRI in vivo: effects on 5-HT cell firing and extracellular 5-HT. Br J Pharmacol. 1995;115(6):1064-70.
46. Dawson LA, Nguyen HQ. Effects of 5-HT1A receptor antagonists on fluoxetine-induced changes in extracellular serotonin concentrations in rat frontal cortex. Eur J Pharmacol. 1998;345(1):41-6.
47. Romero L, Hervas I, Artigas F. The 5-HT1A antagonist WAY-100635 selectively potentiates the presynaptic effects of serotonergic antidepressants in rat brain. Neurosci Lett. 1996;219(2):123-6.
48. De Vry J, Schreiber R, Melon C, Dalmus M, Jentzsch KR. 5-HT1A receptors are differentially involved in the anxiolyticand antidepressant-like effects of 8-OH-DPAT and fluoxetine in the rat. Eur Neuropsychopharmacol. 2004;14(6): 487-95.
49. Tatarczynska E, Klodzinska A, Chojnacka-Wojcik E. Effects of combined administration of 5-HT1A and/or 5-HT1B receptor antagonists and paroxetine or fluoxetine in the forced swimming test in rats. Pol J Pharmacol. 2002;54(6): 615-23.
50. Pauwels PJ. 5-HT 1B/D receptor antagonists. Gen Pharmacol. 1997;29(3):293-303.
51. Porsolt RD, Bertin A, Jalfre M. "Behavioural despair" in rats and mice: strain differences and the effects of imipramine. Eur J Pharmacol. 1978;51(3):291-4.
52. Janssen PA, Jagenau AH, Schellekens KH. Chemistry and pharmacology of compounds related to 4-(4-hydroxy-4- phenyl-piperidino)-butyrophenone. IV. Influence of haloperidol (R 1625) and of chlorpromazine on the behaviour of rats in an unfamiliar "open field" situation. Psychopharmacologia. 1960;1:389-92.